Peloton Wealth Strategists Acquires 2,000 Shares of Zoetis Inc. $ZTS

Peloton Wealth Strategists lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 19.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,497 shares of the company’s stock after purchasing an additional 2,000 shares during the quarter. Peloton Wealth Strategists’ holdings in Zoetis were worth $2,058,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of Zoetis by 0.5% during the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock worth $6,842,222,000 after purchasing an additional 189,287 shares during the period. Polen Capital Management LLC increased its holdings in shares of Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares during the period. Northern Trust Corp increased its holdings in shares of Zoetis by 1.2% during the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after purchasing an additional 78,508 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Zoetis by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock worth $847,293,000 after purchasing an additional 109,791 shares during the period. Finally, Brown Advisory Inc. increased its holdings in shares of Zoetis by 7.6% during the first quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock worth $725,866,000 after purchasing an additional 312,746 shares during the period. 92.80% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on ZTS. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler lifted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Finally, Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and decreased their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $202.43.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $151.88 on Tuesday. The company’s 50 day simple moving average is $153.08 and its 200 day simple moving average is $157.67. The stock has a market capitalization of $67.31 billion, a price-to-earnings ratio of 26.14, a price-to-earnings-growth ratio of 2.46 and a beta of 0.88. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $200.33. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company’s revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.